Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBridge Biosciences (NBP) Non-Current Assets (2018 - 2025)

NovaBridge Biosciences (NBP) has 8 years of Non-Current Assets data on record, last reported at $43.0 million in Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 19.49% to $43.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $162.4 million, a 2.27% decrease, with the full-year FY2025 number at $43.0 million, up 19.49% from a year prior.
  • Non-Current Assets reached $43.0 million in Q4 2025 per NBP's latest filing, down from $44.6 million in the prior quarter.
  • Over the last five years, Non-Current Assets for NBP hit a ceiling of $209.5 million in Q4 2023 and a floor of $23.3 million in Q2 2024.
  • A 5-year average of $90.4 million and a median of $44.6 million in 2025 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: soared 187.68% in 2021, then tumbled 82.82% in 2024.
  • Tracing NBP's Non-Current Assets over 5 years: stood at $188.8 million in 2021, then rose by 6.67% to $201.4 million in 2022, then increased by 4.01% to $209.5 million in 2023, then crashed by 82.82% to $36.0 million in 2024, then grew by 19.49% to $43.0 million in 2025.
  • Business Quant data shows Non-Current Assets for NBP at $43.0 million in Q4 2025, $44.6 million in Q3 2025, and $39.1 million in Q2 2025.